Stay updated on Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe webpage has removed extensive details about a study on pembrolizumab for squamous cell carcinoma, including its purpose, background information, and inclusion/exclusion criteria, while adding minimal new content.SummaryDifference43%
- Check70 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check106 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Unresectable Squamous Skin Cancer Clinical Trial page.